Advertisement

Acute Stroke Emergency Management

  • Scott R. DeBoerEmail author
  • Pravin George
  • Lucia Rivera Lara
Chapter
  • 13 Downloads

Abstract

Acute ischemic stroke management has changed greatly over the last decades. In the 1990s, therapeutic options for acute ischemic stroke were revolutionized with the administration of intravenous tissue plasminogen activator. In 2015, a series of endovascular trials further transformed the therapy for stroke patients. Most recently, two clinical trials have expanded the time-frame for intra-arterial thrombectomy in select patients up to 24 h post-stroke. The following case report and chapter focuses on the diagnosis and management of acute ischemic stroke.

Keywords

Acute ischemic stroke Endovascular Thrombectomy Acute stroke management Stent-retriever Tissue plasminogen activator Stroke imaging 

References

  1. 1.
    Nogueira RG, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Albers GW, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378:708–18.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Powers WJ, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–e110.  https://doi.org/10.1161/STR.0000000000000158.CrossRefGoogle Scholar
  4. 4.
    The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.Google Scholar
  5. 5.
    Hacke W, Kaste M, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke (ECASS III). N Engl J Med. 2008;359:1317–29.CrossRefGoogle Scholar
  6. 6.
    Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke (MR CLEAN). N Engl J Med. 2015;372(1):11–20.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke (ESCAPE). N Engl J Med. 2015;372(11):1019–30.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection (EXTEND IA). N Engl J Med. 2015;372(11):1009–18.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Saver JL, Goyal M, Bonafe A, et al. Solitaire™ with the Intention for thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke. Int J Stroke. 2015;10(3):439–48.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke (REVASCAT). N Engl J Med. 2015;372(24):2296–306.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW, Campbell BC, Nogueira RG, Demchuk AM, Tomasello A, Cardona P, Devlin TG, Frei DF, du Mesnil de Rochemont R, Berkhemer OA, Jovin TG, Siddiqui AH, van Zwam WH, Davis SM, Castaño C, Sapkota BL, Fransen PS, Molina C, van Oostenbrugge RJ, Chamorro Á, Lingsma H, Silver FL, Donnan GA, Shuaib A, Brown S, Stouch B, Mitchell PJ, Davalos A, Roos YB, Hill MD, HERMES Collaborators. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA. 2016;316:1279–88.  https://doi.org/10.1001/jama.2016.13647.
  12. 12.
    Smith EE, Kent DM, Bulsara KR, Leung LY, Lichtman JH, Reeves MJ, Towfighi A, Whiteley WN, Zahuranec D. Accuracy of prediction instruments for diagnosing large vessel occlusion in individuals with suspected stroke: a systematic review for the 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e111–22.  https://doi.org/10.1161/STR.0000000000000160.
  13. 13.
    Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, Erilä T, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Köhrmann M, Larrue V, Lees KR, Machnig T, Roine RO, Toni D, Vanhooren G, for the Safe Implementation of Thrombolysis in StrokeMOnitoring STudy Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke. 2008;39:3316–22.  https://doi.org/10.1161/STROKEAHA.107.510768.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Romano JG, Smith EE, Liang L, Gardener H, Camp S, Shuey L, Cook A, Campo-Bustillo I, Khatri P, Bhatt DL, Fonarow GC, Sacco RL, Schwamm LH. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With The Guidelines-Stroke registry. JAMA Neurol. 2015;72:423–31.  https://doi.org/10.1001/jamaneurol.2014.4354.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Faculty of Medicine, University of Calgary. Understanding Alberta Stroke Program Early CT score (ASPECTS) [Internet] 2015 [Accessed 2 Mar 2016]. http://www.aspectsinstroke.com/aspects/what-is-aspects
  16. 16.
    Hill MD, Demchuk AM, Goyal M. Alberta stroke program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial. Stroke. 2014;45(2):444–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hofmeijer J, Kappelle LJ, Algra A, Amelink GJ, van Gijn J, van der Worp HB. HAMLET investigators. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol. 2009;8(4):326–33.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Jüttler E, Schwab S, Schmiedek P, Unterberg A, Hennerici M, Woitzik J, Witte S, Jenetzky E, Hacke W, DESTINY Study Group. Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke. 2007;38(9):2518–25.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Vahedi K, Vicaut E, Mateo J, Kurtz A, Orabi M, Guichard JP, Boutron C, Couvreur G, Rouanet F, Touzé E, Guillon B, Carpentier A, Yelnik A, George B, Payen D, Bousser MG, DECIMAL Investigators. Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). Stroke. 2007;38(9):2506–17.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Vahedi K, Hofmeijer J, Juettler E, Vicaut E, George B, Algra A, Amelink GJ, Schmiedeck P, Schwab S, Rothwell PM, Bousser MG, van der Worp HB, Hacke W, DECIMAL, DESTINY, and HAMLET Investigators. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007;6:215–22.  https://doi.org/10.1016/S1474-4422(07)70036-4.
  21. 21.
    Bernhardt J, Langhorne P, Lindley RI, et al. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet. 2015;386(9988):46–55.CrossRefGoogle Scholar
  22. 22.
    Paciaroni M, Agnelli G, Falocci N, et al. Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. J Neurol. 2016;263:231–7.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Benjamin EJ, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial brillation after transient ischaemic attack or minor stroke. Lancet. 1993;342(8882):1255–62.CrossRefGoogle Scholar
  25. 25.
    Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.CrossRefGoogle Scholar
  26. 26.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.Google Scholar
  27. 27.
    Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.Google Scholar
  28. 28.
    Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.Google Scholar
  29. 29.
    Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.Google Scholar
  30. 30.
    Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev. 2013;(3):CD008980.Google Scholar
  31. 31.
    Salazar CA, del Aguila D, Cordova EG. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014;(3):CD009893.Google Scholar
  32. 32.
    Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm (WARCEF). N Engl J Med. 2012;366(20):1859–69.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Pullicino PM, Qian M, Sacco RL, et al. Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. Cerebrovasc Dis. 2014;38(3):176–81.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–59.Google Scholar
  35. 35.
    Amarenco P, Benavente O, Goldstein LB, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investiga- tors. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009;40(4):1405–9.Google Scholar
  36. 36.
    Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 2008;359:2195–207.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033–41.CrossRefGoogle Scholar
  38. 38.
    Arauz-Pacheco C, Parrott MA, Raskin P, American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(Suppl 1):S80–2.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–72.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349(9066):1641–9.Google Scholar
  43. 43.
    The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349(9065):1569–81.Google Scholar
  44. 44.
    Rimmele DL, Thomalla G. Wake-up stroke: clinical characteristics, imaging findings, and treatment option—an update. Front Neurol. 2014;5:35.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Thomalla G, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379:611–22.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Urrutia VC, Faigle R, Zeiler SR, et al. Safety of intravenous alteplase within 4.5 hours for patients awakening with stroke symptoms. PLoS One. 2018;13(5):e0197714.  https://doi.org/10.1371/journal.pone.0197714.
  47. 47.
    Markus HS, Hayter E, Levi C, et al. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol. 2015;14(4):361–7.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Kernan WN, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–236.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    He J, Zhang Y, Xu T, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA. 2014;311(5):479–89.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Jüttler E, Unterberg A, Woitzik J, et al. DESTINY II Investigators. Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke. N Engl J Med. 2014;370(12):1091–100.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):123–30.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Baird TA, Muir KW, Bone I. Basilar artery occlusion. Neurocrit Care. 2004;1:319–29.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Schonewille WJ, Wijman CA, Michel P, et al. The basilar artery international cooperation study (BASICS). Int J Stroke. 2007;2(3):220–3.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Singer OC, et al. Mechanical recanalization in basilar artery occlusion: the ENDOSTROKE study. Ann Neurol. 2015 Mar;77(3):415–24.  https://doi.org/10.1002/ana.24336.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014;383(9914):333–41.Google Scholar
  56. 56.
    North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis (NASCET). N Engl J Med. 1991;325(7):445–53.CrossRefGoogle Scholar
  57. 57.
    Ferguson GG, Eliasziw M, Barr HW, et al. The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients. (NASCET). Stroke. 1999;30(9):1751–8.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    International Carotid Stenting Study Investigators, Ederle J, Dobson J, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet. 2010;375(9719):985–97.CrossRefGoogle Scholar
  59. 59.
    Mantese VA, Timaran CH, Chiu D, et al. The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke. 2010;41:S31–4.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Brott TG. Carotid revascularization and medical management for asymptomatic carotid stenosis trial (CREST-2). In: ClinicalTrials.gov [website on the Internet]. Bethseda: US National Library of Medicine; 2014.
  61. 61.
    CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–39.Google Scholar
  62. 62.
    Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation. 2005;111(17):2233–40.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9(5):489–97.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–7.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events (CHARISMA). N Engl J Med. 2006;354:1706–17.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    SPS3 Investigators, Benavente OR, Hart RG, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367(9):817–25.CrossRefGoogle Scholar
  67. 67.
    Lee M, Saver JL, Hong KS, et al. Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. Ann Intern Med. 2013;159(7):463–70.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Wang Y, Wang Y, Zhao X, et al. CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11–9.Google Scholar
  69. 69.
    Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY, Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215–25.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Scott R. DeBoer
    • 1
    Email author
  • Pravin George
    • 2
  • Lucia Rivera Lara
    • 1
  1. 1.Neurosciences Critical Care Division, Department of Anesthesia and Critical Care MedicineJohns Hopkins School of MedicineBaltimoreUSA
  2. 2.Neurocritical Care, Department of NeurologyCleveland ClinicClevelandUSA

Personalised recommendations